CEACAM5 and colorectal cancer: Targets that are frequently pursued by multiple commercial companies include EpCAM in NSCLC, HER2 in advanced breast cancers, prostate-specific membrane antigen (PSMA) in castration-resistant prostate cancers, and carcinoembryonic antigen (CEA) in colorectal cancers [10].